Systemic Delivery of a Targeted Synthetic Immunostimulant Transforms the Immune Landscape for Effective Tumor Regression

To enable tumor-localized immunotherapy following intravenous administration, investigators chemically conjugated a polyspecific integrin-binding peptide (PIP) to an immunostimulant to generate a tumor-targeted immunomodulatory agent, referred to as PIP-CpG.